CD80 antibody

Catalog No. ABIN135272

The Rat Monoclonal anti-CD80 antibody is suitable to detect CD80 in samples from Mouse. It has been validated for FACS, IP and BR.

Quick Overview for CD80 antibody (ABIN135272)

Target: CD80

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This CD80 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunoprecipitation (IP), Blocking Reagent (BR)

Clone: 1G10

Product Details anti-CD80 Antibody

Purpose: Rat Anti-Mouse CD80-LE/AF

Specificity: Mouse CD80, Mr 52-55 kDa

Characteristics: Low Endotoxin/Azide Free Anti-Mouse CD80 antibody for use in flow cytometry, immunoprecipitation, and blocking assays.

Endotoxin Level: Low Endotoxin

Immunogen: Activated 5C2 cells

Isotype: IgG2a

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Phosphate buffered saline, pH 7.4

Preservative: Azide free

Handling Advice: Each reagent is stable for the period shown on the bottle label if stored as directed.

Storage: 4 °C

Storage Comment: 2-8°C

Target Details for CD80

Target: CD80

Alternative Name: CD80

Background: CD80 (B7-1) is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is constitutively expressed by dendritic cells, monocytes, and peritoneal macrophages. Expression of CD80 on B cells is upregulated after activation by various means including stimulation by LPS, IL-4, and surface Ig receptor cross linking with peak expression occurring between 48 and 72 hours post-activation. The interaction of CD80/B7-1 with its ligands, CD28 and CD152/CTLA-4, provides a potent costimulatory signal for T cells activated through the CD3/T cell receptor complex.

Gene ID: 12519

UniProt: Q00609

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints